Valuation: Insmed Incorporated

Market Cap 27.06B 23.22B 21.78B 19.9B 37.54B 2,581B 37.68B 258B 99.99B 1,302B 102B 99.36B 4,309B P/E 2026 *
-78.6x
P/E 2027 * 115x
Enterprise Value 26.42B 22.67B 21.27B 19.44B 36.66B 2,521B 36.8B 252B 97.65B 1,272B 99.21B 97.04B 4,208B EV / Sales 2026 *
14.6x
EV / Sales 2027 * 8.97x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day+0.31%
1 week-3.17%
Current month+26.16%
1 month+16.34%
3 months+17.08%
6 months-16.30%
Current year-28.53%
1 week 121.64
Extreme 121.64
130.27
1 month 96.42
Extreme 96.42
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.21
Extreme 21.21
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
8/17/26 Sell

Director

-5,000 0.0023%
8/10/26 Fiscal year

Chief Operating Officer

719,550 0.3320%
8/6/26 Fiscal year

Chief Technology Officer

81,519 0.0376%
Change 5-day change 1-year change 3-year change Capi.($)
+0.40%-3.17%-3.06%+469.55% 27.06B
+3.31%-3.70%+61.03%+103.64% 71.35B
+2.09%+3.17%+52.14%+91.30% 64.17B
-1.31%+21.36%+7.13%-4.29% 28.65B
-2.78%+4.47%+52.49%+14.43% 27.33B
-1.68%+2.61%+37.12%-16.09% 20.47B
+1.02%+6.43%+269.42%+420.34% 19.36B
-0.57%-4.06%+10.79%+515.61% 15.96B
-1.09%+5.61%+48.02%+155.12% 14.05B
+0.27%+1.39%+330.32%+219.31% 12.55B
Average -0.04%+4.13%+86.54%+196.89% 30.09B
Weighted average by Cap. +0.76%+3.22%+67.21%+156.84%

Financials

2026 *2027 *
Net sales 1.81B 1.55B 1.45B 1.33B 2.51B 172B 2.52B 17.21B 6.68B 86.93B 6.78B 6.63B 288B 2.89B 2.48B 2.32B 2.12B 4B 275B 4.02B 27.49B 10.67B 139B 10.84B 10.6B 460B
Net income -349M -300M -281M -257M -485M -33.33B -487M -3.33B -1.29B -16.81B -1.31B -1.28B -55.64B 211M 181M 170M 156M 293M 20.17B 294M 2.01B 781M 10.17B 794M 776M 33.67B
Net Debt -632M -542M -509M -465M -877M -60.28B -880M -6.02B -2.33B -30.4B -2.37B -2.32B -101B -1.16B -993M -931M -851M -1.6B -110B -1.61B -11.02B -4.27B -55.66B -4.34B -4.25B -184B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-08-26 US$124.39 +0.40% 1,977,270
26-08-25 US$123.89 -0.07% 2,373,321
26-08-24 US$123.98 -1.42% 1,341,042
26-08-21 US$125.77 +0.55% 1,124,491
26-08-20 US$125.08 -4.27% 1,761,850
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
124.39USD
Average target price
200.18USD
Spread / Average Target
+60.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock